Sinphar Pharmaceutical Co.,Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021
November 11, 2021
Share
Sinphar Pharmaceutical Co.,Ltd. reported earnings results for the third quarter and nine months ended September 30, 2021. For the third quarter, the company reported sales was TWD 566.94 million compared to TWD 639.51 million a year ago. Net loss was TWD 33.44 million compared to TWD 9.77 million a year ago. Basic loss per share from continuing operations was TWD 0.2 compared to TWD 0.06 a year ago. Diluted loss per share from continuing operations was TWD 0.2 compared to TWD 0.06 a year ago.
For the nine months, sales was TWD 1,792.18 million compared to TWD 1,847.96 million a year ago. Net loss was TWD 23.1 million compared to net income of TWD 25.55 million a year ago. Basic loss per share from continuing operations was TWD 0.14 compared to basic earnings per share from continuing operations of TWD 0.15 a year ago. Diluted loss per share from continuing operations was TWD 0.14 compared to diluted earnings per share from continuing operations of TWD 0.15 a year ago.
Sinphar Pharmaceutical Co., Ltd. is principally engaged in the research and development, manufacture and distribution of pharmaceuticals. The Company is also engaged in the sales of functional food products. The Companyâs principal products include ointment, gel, cream, hard and soft capsules, sugar-coated tablets, film-coated tablets, suppositories, powders and granules, lozenges, soft candies, oral and topical liquid medicines, injections, dry medicated powers, functional food products, medical equipment and cosmetics. The Company mainly sells its products to hospitals, drug stores, clinics, dealers and distributors. Its primary markets are located in Taiwan and overseas countries.